Trius Therapeutics (TSRX) Posts Narrower Than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts TSRX Hot Sheet
Join SI Premium – FREE
Trius Therapeutics, Inc. (NASDAQ: TSRX) reported Q4 loss of $0.37, $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $1.85 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Movano (MOVE) Misses Q2 EPS by 195c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
